Filing Details
- Accession Number:
- 0000919574-20-005630
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-31 19:33:00
- Reporting Period:
- 2020-08-27
- Accepted Time:
- 2020-08-31 19:33:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
922247 | Cyclo Therapeutics Inc. | CTDH | Industrial Organic Chemicals (2860) | 593029743 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1601086 | Armistice Capital, Llc | 510 Madison Avenue, 7Th Floor New York NY 10022 | No | No | Yes | No | |
1633584 | Ltd. Fund Master Capital Armistice | C/O Dms Corporate Services Ltd. 20 Genesis Close, P.o. Box 314 Grand Cayman E9 KY1-1104 | No | No | Yes | No | |
1706140 | Steven Boyd | C/O Armistice Capital, Llc 510 Madison Avenue, 7Th Floor New York NY 10022 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $.0001 Per Share | Acquisiton | 2020-08-27 | 55,263 | $0.12 | 18,971,787 | No | 4 | S | Direct | |
Common Stock, Par Value $.0001 Per Share | Acquisiton | 2020-08-27 | 0 | $0.00 | 18,971,787 | No | 4 | S | Indirect | See Footnote |
Common Stock, Par Value $.0001 Per Share | Acquisiton | 2020-08-28 | 75,000 | $0.11 | 18,896,787 | No | 4 | S | Direct | |
Common Stock, Par Value $.0001 Per Share | Acquisiton | 2020-08-28 | 0 | $0.00 | 18,896,787 | No | 4 | S | Indirect | See Footnote |
Common Stock, Par Value $.0001 Per Share | Acquisiton | 2020-08-31 | 35,000 | $0.11 | 18,861,787 | No | 4 | S | Direct | |
Common Stock, Par Value $.0001 Per Share | Acquisiton | 2020-08-31 | 0 | $0.00 | 18,861,787 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Direct | |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Direct | |
No | 4 | S | Indirect | See Footnote |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Warrants | $0.27 | 2019-05-31 | 2024-11-30 | 12,000,000 | 12,000,000 | Direct |
Common Stock | Warrants | $0.27 | 2019-05-31 | 2024-11-30 | 12,000,000 | 12,000,000 | Indirect |
Common Stock | Warrants | $0.15 | 2020-08-27 | 2027-08-27 | 10,000,000 | 10,000,000 | Direct |
Common Stock | Warrants | $0.15 | 2020-08-27 | 2027-08-27 | 10,000,000 | 10,000,000 | Indirect |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2024-11-30 | 12,000,000 | 12,000,000 | Direct |
2024-11-30 | 12,000,000 | 12,000,000 | Indirect |
2027-08-27 | 10,000,000 | 10,000,000 | Direct |
2027-08-27 | 10,000,000 | 10,000,000 | Indirect |
Footnotes
- The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- This constitutes the weighted average purchase price. The prices ranged from $0.11 to $0.12. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Stock, par value $.0001 per share, following such exercise.